[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100349178":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":59,"collaborators":18,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":18,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Sclnow Biotechnology Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6\\*10\\^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 \\* 10 \\^ 7 (30 ml)",[13],"Biological: Peripheral iv",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Control Group: Using basic contrast .",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BIOLOGICAL","Peripheral iv","6\\*10\\^7 cells",[9],[26],{"name":27,"affiliation":28,"role":29},"Xuegong Fan, doctor","Xiangya Hospital of Central South University","STUDY_DIRECTOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Lei Guo, doctor","CONTACT","861064368977","georgeguo@sclnow.com",{"name":27,"role":33,"phone":37,"phoneExt":18,"email":38},"86731-84327392","xgfan@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Xiangya Hospital Central South University","RECRUITING","Changsha","Hunan","410008","China","CN",{"type":49,"coordinates":50},"Point",[51,52],112.97087,28.19874,{"lat":52,"lon":51},[55,58],{"name":56,"role":33,"phone":57,"phoneExt":18,"email":18},"ShaLing Li, doctor","8613975186154",{"name":27,"role":33,"phone":37,"phoneExt":18,"email":38},{"type":60,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100349178","phase-1-huc-mesenchymal-stem-cells-19isclife-lc-in-the-treatment-of-decompensated-hepatitis-b-cirrhosishepatitis-b-cirrhosis-100349178",false,"NCT03826433","hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosis","Inclusion Criteria:\n\n* Age 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg\u002Fm2, including boundary value;\n* The diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score≤21 points.\n* Have not received stem cell therapy in the recent 6 months;\n* Subjects will be able to sign the informed consent in accordance with the study procedures and instructions.\n\nExclusion Criteria:\n\n* Insufficiency of vital organs, such as heart, kidney and lung;\n* End-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc.\n* Concomitant peritonitis, pneumonia, or other types of infection not under control;\n* Have a history of severe allergic reaction or allergy to two or more kinds of food or medicine;\n* Positive serum HIV antibody and syphilis antibody;\n* Alpha fetoprotein\\>400ng\u002FmL with primary liver cancer or without imaging evidence;\n* Chronic liver disease and cirrhosis are caused by non-chronic hepatitis B virus infection, or other factors except chronic hepatitis B virus infection ;\n* Patients with severe mental illness and cognitive impairment;","ALL","18 Years","60 Years",{"count":72,"type":73},20,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.\n2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat.\n3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.",[79],"Hepatitis B",[81],"Hepatitis B Cirrhosis, mesenchymal stem cell","2026-04-22",{"date":84,"type":85},"2026-04-23","ACTUAL",{"date":87,"type":85},"2018-10-01",{"date":89,"type":73},"2027-12-31",{"name":5,"class":6},1]